[The correction of the immune system by using the immunomodulator ribomunyl in patients with recurrent respiratory tract infections].

Children and adults with chronic ENT and bronchopulmonary infections took ribomunyl tablets (Pierre Fabre) under immunological control. Even a 3 week course led to obvious clinical improvement of their condition in acute stage. Investigation of populations and subpopulations of lymphocytes showed that ribomunyl mainly increases the number of CD3+, CD3+4+, CD3-/16+56-, CD4+25+, CD4+69+, CD56+25+. CD56-25+ and CD8-38+ cells that is increased the number of T-, T-n and NK-cells and also increased expression on T-n and NK-cells of activation antigens. An increase in quantity and activation of these cells was more expressed in patients with initially smaller number of these cells and correlated with the treatment efficacy. Ribomunyl enhanced effector function of NK-cells, phagocytes (monocytes and granulocytes), this activation being more in patients with marked clinical effect. Ribomunyl appeared effective in Chernobyl accident victims also. A long-term course of ribomunyl (6 months) showed better clinical effect when compared to 3-week course.